Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index; none of the 98 sources its claims cite is checked for support yet.
Abstract
To understand and treat immunology-related diseases, a comprehensive, unbiased characterization of major histocompatibility complex (MHC) peptide ligands is of key importance. Preceding the analysis by mass spectrometry, MHC class I peptide ligands are typically isolated by MHC immunoaffinity chromatography (MHC-IAC) and less often by mild acid elution (MAE). MAE may provide a cheap alternative to MHC-IAC for suspension cells but has been hampered by the high number of contaminating, MHC-unrelated peptides. Here, we optimized MAE, yielding MHC peptide ligand purities of more than 80%. When compared with MHC-IAC, obtained peptides were similar in numbers, identities, and to a large extent intensities, while the percentage of cysteinylated peptides was 5 times higher in MAE. The latter benefitted the discovery of MHC-allotype-specific, distinct cysteinylation frequencies at individual positions of MHC peptide ligands. MAE revealed many MHC ligands with unmodified, N-terminal cysteine residues which get lost in MHC-IAC workflows. The results support the idea that MAE might be particularly valuable for the high-confidence analysis of post-translational modifications by avoiding the exposure of the investigated peptides to enzymes and reactive molecules in the cell lysate. Our improved and carefully documented MAE workflow represents a high-quality, cost-effective alternative to MHC-IAC for suspension cells.
Overview
CoChat Summary
TL;DR
Optimized mild acid elution (MAE) yields HLA class I peptide purities above 80% and peptide numbers, identities, and MS1 intensities largely comparable to MHC immunoaffinity chromatography (MHC-IAC). MAE recovers about 5-fold more cysteinylated peptides and better preserves N-terminal unmodified cysteine residues, making it a cost-effective alternative for suspension cells, though it remains unsuitable for solid tissue or frozen cells.
Key findings
- Optimized MAE achieved >80% MHC peptide ligand purity; >82% of identified 8–12-mers were assigned to an appropriate MHC allotype using NetMHC IC50 <500 nM. MAE yielded 9% (JY) to 30% (THP-1) fewer peptides than MHC-IAC. Of 2072 total JY peptides, 50% were found by both methods; of 1268 THP-1 peptides, 36% were shared. Strong binders overlapped 55% (JY) and 41% (THP-1), while putative contaminants overlapped only 17% (JY, 32/189) and 7% (THP-1, 12/168).
- Quantitative MS1 data correlated between MAE and MHC-IAC with R² = 0.65 (JY) and R² = 0.62 (THP-1); 69.3% and 63.2% of shared peptides differed by less than 2-fold in mean MS1 intensity. The overall median MS1 intensity of identified MHC ligands differed by less than 2% between extraction methods.
- MAE showed on average >5-fold higher relative cysteinylated peptides than MHC-IAC: mean 2.91% vs 0.53% (P = 2.6 × 10⁻⁶). Cysteinylation was enriched among HLA-A*02:01 binders and diminished among HLA-B*07:02 binders; preferred at position C-1 for both allotypes, and at C-4 for HLA-A*02:01 but not HLA-B*07:02. MAE also revealed carbamidomethylated N-terminal cysteine residues.
- In MHC-IAC, acetonitrile-based ultrafilter rinsing yielded 2–3 times more peptide identifications and boosted MS1 intensities 27-fold and 41-fold versus the first ultrafiltrate, especially for hydrophobic peptides. Repeated MAE recovered only 2.1% and 3.5% of peptides relative to the first MAE, indicating acidic elution was nearly complete; <2% of cells survived the repeated MAE.
Methods
- Direct comparison of optimized MAE and MHC-IAC starting from the same cell cultures, primarily JY and THP-1 suspension cells (LCL5 also described in Methods). MAE used 5 × 10⁸ JY cells and 1.25 × 10⁸–1.5 × 10⁹ THP-1 cells; MHC-IAC used W6/32 for HLA-A, -B, -C and L243/Tü39 for MHC-II.
- Peptides were analyzed by LC-MS/MS on an LTQ Orbitrap XL and an Orbitrap Fusion. Data were processed with Proteome Discoverer, Mascot/Sequest, and Percolator with a peptide spectral match FDR ≤5%; searches allowed 8–12-mers and variable modifications including oxidation, cysteinylation, and carbamidomethylation.
- Analyses included peptide overlap, MS1 intensity correlation, MHC allotype assignment via NetMHC/Syfpeithi, positional cysteinylation frequencies, repeated MAE, organic-solvent elution tests, and acetonitrile ultrafilter rinsing. Structural exposure measures used selected HLA-A*02:01 and HLA-B*07:02 PDB crystal structures.
Limitations
- Stated: MAE is not applicable to solid tissue, appears unsuitable for frozen cells, and cannot sample MHC-II; MHC-IAC remains necessary for solid tissues and frozen cells. Repeated MAE is not beneficial because it causes substantial cellular stress, with <2% cell survival.
- Stated: the relative contribution of W6/32 antibody bias versus sample-processing bias could not be deduced from this study, and additional studies are needed. The structural explanation for cysteinylation patterns remains a hypothesis requiring crystal structures with cysteinylated MHC peptide ligands. HLA-B*07:02 structural analysis was limited by only four PDB entries, two of which were putatively not representative.
- Evident from the text: the main comparison focused on two suspension cell lines and a limited set of HLA allotypes; MHC-IAC was deliberately performed without cysteine protection for representativeness, which may affect cysteine-related comparisons. MAE by design samples only cell-surface MHC-I and excludes intracellular MHC compartments.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 2 Not valid · 61 Not checked · 171 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As expected, MHC-IAC yielded an even higher fraction of peptides of the appropriate length (99% for JY and 98% for THP-1, Supplementary Figure S6).”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Share Generic Features
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Specifically, MAE yielded 9% (JY cells) to 30% (THP-1 cells) fewer peptides than MHC-IAC but also revealed MHC peptide ligands not detected by MHC-IAC.”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Largely Overlap
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but even LC-MS triplicates of one and the same sample provided only 64% overlap due to the stochastic nature of the applied data dependent acquisition (DDA) MS scheme (Supplementary Figure S3E).”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Largely Overlap
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In MAE, the summed fraction of 8- to 12-mers among all identified peptides was 96% (JY) and 90% (THP-1), respectively”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Share Generic Features
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Comparing MAE versus MAE or MHC-IAC versus MHC-IAC from a single cell culture harvesting (like in the comparison of MAE and MHC-IAC), the overlap was higher”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Largely Overlap
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
153 more claims
Create a free account to see all 234 claims and to verify the 96 references still open.
- It may state two separate claims as one. 45
- The quote only partly states this claim. 2
- Probably not a substantial claim. 34
Citations
Cites
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484
2016 update of the PRIDE database and its related tools
Vizcaíno, J. A., Csordas, A., del-Toro, N., Dianes, J. A., Griss, J., Lavidas, I., Mayer, G., Perez-Riverol, Y., Reisinger, F., Ternent, T., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1145 · Cited by 3,451
Semi-supervised learning for peptide identification from shotgun proteomics datasets
Käll, L., Canterbury, J. D., Weston, J., Noble, W. S., & MacCoss, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1113 · Cited by 2,424
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
Self-citationSYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H. G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,314
Self-citationEstablishment and characterization of a human acute monocytic leukemia cell line (THP‐1)
Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Konno, T., & Tada, K. (1980) · International Journal of Cancer · doi:10.1002/ijc.2910260208 · Cited by 2,254
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044 · cited 1×
“6 The sum of all MHC peptide ligands from a given biological entity is referred to as the MHC peptide ligandome or the MHC immunopepti-dome.”
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citationBarnstable, C. (1978) · Cell · doi:10.1016/0092-8674(78)90296-9 · Cited by 1,916
Olsen, J. V., de Godoy, L. M. F., Li, G., Macek, B., Mortensen, P., Pesch, R., Makarov, A., Lange, O., Horning, S., & Mann, M. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t500030-mcp200 · Cited by 1,510
Cited by
AlphaPeptDeep: a modular deep learning framework to predict peptide properties for proteomics
Zeng, W.-F., Zhou, X.-X., Willems, S., Ammar, C., Wahle, M., Bludau, I., Voytik, E., Strauss, M. T., & Mann, M. (2022) · Nature Communications · doi:10.1038/s41467-022-34904-3 · Cited by 213
Peptide-based vaccine for cancer therapies
Buonaguro, L., & Tagliamonte, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210044 · Cited by 110
Proteomic discovery of chemical probes that perturb protein complexes in human cells
Lazear, M. R., Remsberg, J. R., Jaeger, M. G., Rothamel, K. L., Her, H.-L., DeMeester, K. E., Njomen, E., Hogg, S. J., Rahman, J. A., Whitby, L. R., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.03.026 · Cited by 93
Klaeger, S., Apffel, A. M., Clauser, K. R., Sarkizova, S., Oliveira, G., Rachimi, S., Le, P. M., Tarren, A. Y., Chea, V. A., Abelin, J. G., et al. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100133 · Cited by 54
Nelde, A., Schuster, H., Heitmann, J. S., Bauer, J., Maringer, Y., Zwick, M., Volkmer, J.-P., Chen, J. Y., Stanger, A. M. P., Lehmann, A., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0020 · Cited by 35
Self-citationFlender, D., Vilenne, F., Adams, C., Boonen, K., Valkenborg, D., & Baggerman, G. (2024) · Mass Spectrometry Reviews · doi:10.1002/mas.21905 · Cited by 33
The biogenesis of the immunopeptidome
Admon, A. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101766 · Cited by 32
Stutzmann, C., Peng, J., Wu, Z., Savoie, C. J., Sirois, I., Thibault, P., Wheeler, A. R., & Caron, É. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100511 · Cited by 30
Isolation of HLA Bound Peptides by Immunoaffinity Capture and Identification by Mass Spectrometry
Pandey, K., Ramarathinam, S. H., & Purcell, A. W. (2021) · Current Protocols · doi:10.1002/cpz1.92 · Cited by 26
Hoek, M., Demmers, L. C., Wu, W., & Heck, A. J. R. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00466 · Cited by 23
Self-citationMinegishi, Y., Kiyotani, K., Nemoto, K., Inoue, Y., Haga, Y., Fujii, R., Saichi, N., Nagayama, S., & Ueda, K. (2022) · Communications Biology · doi:10.1038/s42003-022-03807-w · Cited by 23
Using mass spectrometry to identify neoantigens in autoimmune diseases: The type 1 diabetes example
Lichti, C. F., & Wan, X. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101730 · Cited by 22
Immunopeptidogenomics: Harnessing RNA-Seq to Illuminate the Dark Immunopeptidome
Scull, K. E., Pandey, K., Ramarathinam, S. H., & Purcell, A. W. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100143 · Cited by 22
Balakrishnan, A., Winiarek, G., Hołówka, O., Godlewski, J. A., & Bronisz, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1540431 · Cited by 20
Bernhardt, M., Cruz-Garcia, Y., Rech, A., Meierjohann, S., Erhard, F., Schilling, B., & Schlösser, A. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c02198 · Cited by 18
Xu, P., Woodhouse, I. B., Hancock, G., Parker, R. S., Marx, K., Müller, J., Salatino, S., Partridge, T., Nicastri, A., Liao, H., et al. (2022) · iScience · doi:10.1016/j.isci.2023.106101 · Cited by 17
Development of Cancer Immunotherapies
DeLucia, D. C., & Lee, J. K. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_1 · Cited by 16
Juanes‐Velasco, P., Landeira‐Viñuela, A., Acebes-Fernández, V., Hernández, Á., García‐Vaquero, M. L., Arias‐Hidalgo, C., Bareke, H., Montalvillo, E., Góngora, R., & Fuentes, M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642583 · Cited by 16
Immunoprecipitation methods impact the peptide repertoire in immunopeptidomics
Wacker, M., Bauer, J., Wessling, L., Dubbelaar, M. L., Nelde, A., Rammensee, H., & Walz, J. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1219720 · Cited by 16
Self-citationNew insights and approaches for analyses of immunopeptidomes
Illing, P. T., Ramarathinam, S. H., & Purcell, A. W. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102216 · Cited by 15
NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity
Santharam, M. A., Shukla, A., Lévesque, D., Kufer, T. A., Boisvert, F., Ramanathan, S., & Ilangumaran, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087206 · Cited by 13
Joyce, S., & Ternette, N. (2021) · PROTEOMICS · doi:10.1002/pmic.202000143 · Cited by 10
Tian, H., Li, G., Chiu, C. K. C., Li, E. L., Chen, Y., Zhu, T., Hu, M., Wang, Y., Wen, S., Li, J., et al. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100251 · Cited by 10
Prašnikar, E., Perdih, A., & Borišek, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925427 · Cited by 8
Larson, A. C., Knoche, S. M., Brumfield, G. L., Doty, K. R., Gephart, B. D., Moore-Saufley, P. R., & Solheim, J. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063211 · Cited by 8
Immunogenicity of Non-Mutated Ovarian Cancer-Specific Antigens
Hesnard, L., Thériault, C., Cahuzac, M., Durette, C., Vincent, K., Hardy, M., Lanoix, J., Lavallée, G. O., Humeau, J., Thibault, P., et al. (2024) · Current Oncology · doi:10.3390/curroncol31060236 · Cited by 6
Bathini, M., Bocaniciu, D., Johnson, F. D., de Jong, R. C. P., Yu, F., Aloi, V. D., Kuiken, M. C., Mors, J. R., Giebel, L., Champagne, J., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09570-6 · Cited by 6
Nielsen, M., Ternette, N., & Barra, C. (2022) · Expert Review of Proteomics · doi:10.1080/14789450.2022.2064278 · Cited by 6
Crucial Parameters for Immunopeptidome Characterization: A Systematic Evaluation
Juanes‐Velasco, P., Arias‐Hidalgo, C., García‐Vaquero, M. L., Sotolongo-Ravelo, J., Paíno, T., Lécrevisse, Q., Landeira‐Viñuela, A., Góngora, R., Hernández, Á., & Fuentes, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179564 · Cited by 5
Small Molecule Modulation of MHC-I Surface Expression: A Click Chemistry-Based Discovery Approach
Newkirk, S. E., Kelly, J. J., Chordia, M. D., Dou, Y., Zhang, T., & Pires, M. M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01149 · Cited by 5
COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome
Wang, F., Zhang, Z., Mao, M., Yang, Y., Xu, P., & Lu, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04821-0 · Cited by 5
Current LC methods for the separation and analysis of peptides and proteins
Viglio, S., D’Amato, M., & Iadarola, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99969-4.00029-2 · Cited by 5
Ternette, N., Adamopoulou, E., & Purcell, A. W. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101780 · Cited by 4
A Platform for High-throughput and Ultrasensitive Immunopeptidomics
Gul, A., Moortel, L. V., Willems, P., Aernout, I., Pedró-Cos, L., Ferrell, K. C., Boucher, K. L., Staes, A., Devos, S., Lentacker, I., et al. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101590 · Cited by 4
MAETi: Mild acid elution in a tip enables immunopeptidome profiling from 1E4 cellsPreprint
Beyrle, J., Yamasaki, Y., Ford, M., Conche, C., Chen, Y., Arnold, A., Pecori, R., Distler, U., Gomez‐Zepeda, D., & Tenzer, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.20.628848 · Cited by 4
Biomarkers and advances in AML-MRC: from bench to bedside
Meng, F., Al-Khafaji, Z., Muzammil, K., Sarbazjoda, E., Khaksari, M. N., Bayani, A., & Samarkhazan, H. S. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06805-8 · Cited by 3
Kehm, H., Zens, S., Baumann, D., Meng, Z., de Ru, A. H., Tjokrodirijo, R. T. N., Vent, C., Murawjew, O., Braun, S., Weiß, A., et al. (2026) · Science Advances · doi:10.1126/sciadv.adr6132 · Cited by 3
Bedran, G., Wang, T., Pankanin, D., Weke, K., Laird, A., Battail, C., Zanzotto, F. M., Pesquita, C., Axelson, H., Rajan, A., et al. (2022) · SSRN Electronic Journal · doi:10.1101/2022.01.13.475872 · Cited by 3
Mecklenbräuker, S., Skoczylas, P., Biernat, P., Zaghla, B. K. Q., Atay, B., Hossam, M., Król-Józaga, B., Jasiński, M., Pienkowski, V. M., Sanecka-Duin, A., et al. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101560 · Cited by 3
Framework for analyzing MAE-derived immunopeptidomes from cell lines with shared HLA haplotypes
Chan, Q. W. T., Baker, T. C., Kuan, C.-W., Song, L., Yu, H., & Foster, L. J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0332950 · Cited by 2
A Globally Representative Immunopeptidomics Approach to Identify Population-Wide Vaccine CandidatesPreprint
Baker, T. C., Song, L., Cai, C., Gu, S., & Foster, L. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.25.690604 · Cited by 1
You are what you degrade: tracking the cellular fates of the proteasomal degradome
Dantis, D. S., & Trader, D. J. (2026) · Molecular Omics · doi:10.1093/momics/aaiaf002 · Cited by 1
Probing highly polymorphic proteins by mass spectrometry: Proteins with a personalized touch
Hoek, M. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1535
Improved immunopeptidomics analysis methods for cancer antigen discovery
Demmers, L. C. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/924
Liu, S., Gao, Y., Liu, Q., Yang, R., Li, J., & Guo, Z. (2026) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/csb-2026-0582
Oncolytic Virus‐Engineered Extracellular Vesicles Rewire Glioblastoma Immunity
Kiel, K., Balakrishnan, A., Cabaj, A., Stanaszek, L., Przybylski, M., Stępnik, D., Małuszek, M., Jannotta, C., Linke, C. Z., Suszyńska-Zajczyk, J., et al. (2026) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70389
Rijal, R., & Marques, A. F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1824717
Identification of tumor antigens for T-cell-mediated cancer immunotherapy
Rammensee, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823901-8.00010-8
Self-citationFast, E., Dhar, M., Gulati, G. S., Ku, M., & Chen, B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.08.730987
Wang, F., Zhang, Z., Mao, M., Yang, Y., Xu, P., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26679401
Wang, F., Zhang, Z., Mao, M., Yang, Y., Xu, P., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26679389
Wang, F., Zhang, Z., Mao, M., Yang, Y., Xu, P., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26679404
Wang, F., Zhang, Z., Mao, M., Yang, Y., Xu, P., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.25200555
Wang, F., Zhang, Z., Mao, M., Yang, Y., Xu, P., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26679392
Wang, F., Zhang, Z., Mao, M., Yang, Y., Xu, P., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.25200750
Wang, F., Zhang, Z., Mao, M., Yang, Y., Xu, P., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26679398
Wang, F., Zhang, Z., Mao, M., Yang, Y., Xu, P., & Lu, S. (2024) · Figshare · doi:10.6084/m9.figshare.26679395
Proteogenomic peptide discovery in large search spaces
Horokhovskyi, Y. (2025) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-11048
Wacker, M., Bauer, J., Wessling, L., Dubbelaar, M., Nelde, A., Rammensee, H.-G., & Walz, J. S. (2023) · doi:10.3389/fimmu.2023.1219720.s003
Self-citationLeoni, M., Dierickx, M., Miranda, M., Langerhorst, P., van der Zwaan, C., Mul, E. P. J., Hoogendijk, A. J., Fijnvandraat, K., & Voorberg, J. (2026) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2026.106786
Mitigating methionine oxidation in mass spectrometry-based immunopeptidomics
Francis, R., Baymaz, H. I., Carreira, R. J., & Jones, A. W. (2026) · Journal of Proteomics · doi:10.1016/j.jprot.2026.105750
Prašnikar, E., Perdih, A., & Borišek, J. (2022) · doi:10.3389/fphar.2022.925427.s001
Metadata
- Authors
- Sturm, T., Sautter, B., Wörner, T. P., Stevanović, S., Rammensee, H.-G., Planz, O., Heck, A. J. R., & Aebersold, R.
- Affiliations
- Utrecht University (NL)
- University of Tübingen (DE)
- Utrecht University , , ,
- University of Tübingen , , ,
- University of Zurich (CH)
- Corresponding author
- Sturm, Theo
- Aebersold, Ruedi
- Venue
- Journal of Proteome Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-11-03
- Volume
- 20
- Issue
- 1
- Pages
- 289-304
- ISSN
- 1535-3893 (ISSN-L)
- 1535-3907
- PMC
- PMC7786382
- OpenAlex
- W3097954807
- Cited by
- 63
- References
- 71
- Citations by year
- 2026: 12 · 2025: 6 · 2024: 14 · 2023: 12 · 2022: 12 · 2021: 7
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Proteome Research (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository for Publications and Research Data (ETH Zurich) (publishedVersion, cc-by-nc-nd)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- ETH Zürich Research Collection (cc-by-nc-nd)
- Funders
- Horizon 2020 Framework Programme (2-73838-14)
- H2020 European Research Council (670821, ERC-2008-AdG_20080422)
- H2020 Future and Emerging Technologies (686547)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (3100A0-688 107679)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (SPI.2017.028)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- immunopeptidome, cysteine modification, post-translational modification, peptide purification, suspension-cultured cells
- MeSH terms
- Chromatography, Affinity, Cysteine, Peptides, Protein Binding, Mass Spectrometry, Histocompatibility Antigens Class I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.